Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

doi:10.1200/JCO.2015.63.4238

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2015

André Thierry, de Gramont Armand, Vernerey Dewi, Chibaudel Benoist, Bonnetain Franck, Tijeras-Raballand Annemilaï, Scriva Aurelie, Hickish Tamas, Tabernero Josep, Van Laethem Jean Luc, Banzi Maria, Maartense Eduard, Shmueli Einat, Carlsson Goran U, Scheithauer Werner, Papamichael Demetris, Möehler Marcus, Landolfi Stefania, Demetter Pieter, Colote Soudhir, Tournigand Christophe, Louvet Christophe, Duval Alex, Fléjou Jean-François, de Gramont Aimery

Abstract excerpt

PURPOSE: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. METHODS: Survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Fluorouracil

Share to Infusions, Intravenous

Share to Injections, Intravenous

Share to Leucovorin

Share to Organoplatinum Compounds

Share to Valine

Source

Open in PubMed

Identifiers

PMID: 26527776
DOI: 10.1200/JCO.2015.63.4238

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.PMID 26527776Read ↗

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.Semantic proximity Read ↗

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.Semantic proximity Read ↗

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.Semantic proximity Read ↗

Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.Semantic proximity Read ↗

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.Semantic proximity Read ↗

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.Semantic proximity Read ↗

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based studySemantic proximity Read ↗

Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.Semantic proximity Read ↗

KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.Semantic proximity Read ↗

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.Semantic proximity Read ↗

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.